EUVIMEDEUVIMED entdecken
Open Access

BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin’s Lymphoma Patients: A Single Center Real-Life Experience

Ant Uzay, Elif Şenocak Taşçı iD, Yasemin Gündoğdu, Arda Ulaş Mutlu, Tuğba Yetiş, Barış Koşan, Sami Kartı

Indian Journal of Hematology and Blood Transfusion · 2025-10 · 41 (4) · 828-835

DOI: 10.1007/s12288-024-01924-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Hematology and Blood Transfusion, online erschienen am 28.11.2024. Verfasst von Ant Uzay und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Acıbadem MAA University Atakent Hospital, Istanbul, Turkey. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal goal in the management of refractory/relapsed classical Hodgkin lymphoma (R/R-cHL) is to obtain minimal disease status before stem cell transplantation (SCT). The efficiency of BEGEV (bendamustin, gemcitabine, vinorelbine) regimen is well-established as first-line salvage therapy in earlier studies. The search for novel treatment continues for patients with limited options in later lines. This study aimed to evaluate the efficacy of BEGEV regimen in heavily pretreated, platinum-resistant, R/R-cHL.

Methods

In this single-center retrospective trial, patients diagnosed with R/R-cHL between 2018 and 2023 were analyzed. Patients who received BEGEV in third- or fourth-line treatment were eligible. Patient's demographic characteristics, pathology results, treatment and survival outcomes were recorded. Overall survival (OS), objective response rate (ORR), progression free survival (PFS) and toxicity were analyzed.

Results

A total of 31 patients were included in this study. 27 (87.2%) patients were treated with BEGEV in the 3rd line and 4 (12.8%) patients were treated in the 4th line. The results show an ORR of 90.3%, with 54.9% achieving complete response. The median PFS and OS after the BEGEV regimen was 20.2 (range 15-23.6) and 23.2 (range 15.4-40.8) months, respectively. The regimen demonstrated acceptable toxicity, with the most common severe adverse events being neutropenia and thrombocytopenia. SCT was successfully performed in 100% of the patients after BEGEV treatment.

Conclusion

Our findings suggest that BEGEV is a viable and effective treatment option for heavily pretreated, platinum-resistant R/R-cHL patients, particularly in regions with limited access to novel therapies.

Schlagwörter

Stichwörter der Autor:innen

BEGEVHodgkinLymphomaPlatinum-resistantPretreatedRelaped-refractory

Autor:innen und Institutionen

  • Department of Hematology, Acıbadem MAA University Atakent Hospital, Istanbul, Turkey.
  • Department of Medical Oncology, SBU Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey.
  • Department of Internal Medicine, Acıbadem MAA University, Istanbul, Turkey.
  • Department of Medicine, Acıbadem MAA University, Istanbul, Turkey.

ORCID-Profile: Elif Şenocak Taşçı

Zitieren

APA

Uzay, A., Taşçı, E. Ş., Gündoğdu, Y., Mutlu, A. U., Yetiş, T., Koşan, B., & Kartı, S. (2025). BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin’s Lymphoma Patients: A Single Center Real-Life Experience. Indian Journal of Hematology and Blood Transfusion, 41(4), 828-835. https://doi.org/10.1007/s12288-024-01924-6

Vancouver

Uzay A, Taşçı EŞ, Gündoğdu Y, Mutlu AU, Yetiş T, Koşan B, et al. BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin’s Lymphoma Patients: A Single Center Real-Life Experience. Indian Journal of Hematology and Blood Transfusion. 2025;41(4):828-835. doi:10.1007/s12288-024-01924-6

BibTeX
@article{Uzay2025,
  author = {Uzay, Ant and Taşçı, Elif Şenocak and Gündoğdu, Yasemin and Mutlu, Arda Ulaş and Yetiş, Tuğba and Koşan, Barış and Kartı, Sami},
  title = {BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin’s Lymphoma Patients: A Single Center Real-Life Experience},
  journal = {Indian Journal of Hematology and Blood Transfusion},
  year = {2025},
  volume = {41},
  number = {4},
  pages = {828--835},
  doi = {10.1007/s12288-024-01924-6}
}
Kostenlos starten →